Reata Pharmaceuticals, Inc.

In what observers are calling a sensible deal for both sides, Stoke Therapeutics and Biogen revealed on 18 February that they will collaborate on development and commercialization of Stoke’s antisense

CEO Christopher Viehbacher has been straightforward about Biogen’s challenges since taking the helm in November 2022, and that did not change as the company reported its fourth-quarter and full-year 2

The development road has been a rocky one for PTC Therapeutics, Inc. 's vatiquinone but the company has unveiled long-term data which will provide support for a regulatory filing in the rare neuromus

Another day and another deal in the molecular glue degrader (MGD) space has been inked, with Biogen the latest major company keen to explore the potential of protein degradation for previously undrugg